VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE)

31 filings reported holding VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q3 2024.
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7.31M shares of 16.7M outstanding shares and own 43.89% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (1.39M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.39M shares), CITADEL ADVISORS LLC (1.19M shares), DSC Advisors, L.P. (696K shares), Palo Alto Investors LP (445K shares), VANGUARD GROUP INC (444K shares), Exome Asset Management LLC (353K shares), AlphaCentric Advisors LLC (268K shares), Parkman Healthcare Partners LLC (203K shares), and Schonfeld Strategic Advisors LLC (169K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.